Northwest Biotherapeutics, Inc. (NWBO) presents GBM Brain Cancer Survival Story of Brad Silver

Northwest Biotherapeutics (OTCBB: NWBO) is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance
immune system responses to treat cancer.

NWBO's DCVax® is a personalized and highly economical cancer vaccine developed from a patient's own immune cells, using biomarkers from the patient's own brain tumor cells. DCVax® has shown stunning and consistent positive results in clinical trials over the past eight years by greatly delaying the time to disease progression (i.e., tumor
recurrence), and substantially extending the survival time for patients. Patients who have received DCVax® in clinical trials to date have shown unprecedented survival, and negligible side effects.

Personalized immune cell therapies such as NWBO's DCVax® hold real hope and increasingly demonstrated promise for patients.

For more information please visit www.NWBio.com.

Category:

News & Politics

Tags:

• GBM
• Brain Cancer
• Clinical Trials
• Glioblastoma Multiforme
• Cancer Treatment
• Dendritic Cells
• Stage 4
• Brain Tumor
• Prostate Cancer
• Cancer Therapy
• Cancer Survivors
• Northwest Biotherapeutics
• NWBO
• DCVax
• DCVax®
• NWBT
• NWBio